Targeting gp130 to prevent inflammation and promote insulin action
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Obesity and type 2 diabetes are now the most prevalent metabolic diseases in the Western world and the development of new strategies to treat these metabolic diseases is most warranted. Obesity results in a state of chronic low‐grade inflammation in metabolically active tissues such as the liver, adipose tissue, brain and skeletal muscle. Work in our laboratory has focussed on the role of the cytokine interleukin‐6 ( IL )‐6 and other IL ‐6‐like cytokines that signal through the gp130 receptor complex. We have focussed on the role of blocking IL ‐6 trans‐signalling to prevent inflammation on the one hand, and activating membrane‐bound signalling to promote insulin sensitivity on the other hand. Since the cloning of the IL ‐6 gene nearly 30 years ago, a pattern has emerged associating IL ‐6 with a number of diseases associated with inflammation including rheumatoid arthritis ( RA ), Crohn's disease and several cancers. Accordingly, tocilizumab, an IL ‐6 receptor‐inhibiting monoclonal antibody, is now useful for the treatment of RA . However, this may not be the most optimal strategy to block inflammation associated with IL ‐6 and may result in unwanted side effects that, paradoxically, could actually promote metabolic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Muscle as an Endocrine Organ: Focus on Muscle-Derived Interleukin-6
Pedersen, B. K., & Febbraio, M. A. (2008) · Physiological Reviews · doi:10.1152/physrev.90100.2007 · Cited by 2,388 · cited 1×
“Apart from the effects of IL-6 on glucose metabolism, several studies have reported that IL-6 can increase intramuscular or whole body fatty acid oxidation (for review see [45]).”
BackgroundSelf-citationIKK-β links inflammation to obesity-induced insulin resistance
Arkan, M. C., Hevener, A. L., Greten, F. R., Maeda, S., Li, Z.-W., Long, J. M., Wynshaw-Boris, A., Poli, G., Olefsky, J., & Karin, M. (2005) · Nature Medicine · doi:10.1038/nm1185 · Cited by 1,773
Interleukin-6-deficient mice develop mature-onset obesity
Wallenius, V., Wallenius, K., Ahrén, B., Rudling, M., Carlsten, H., Dickson, S. L., Ohlsson, C., & Jansson, J.-O. (2002) · Nature Medicine · doi:10.1038/nm0102-75 · Cited by 1,213 · cited 1×
“Initial studies demonstrated that global IL-6 knockout mice display mature onset obesity [21], and subsequent studies by our group showed that global IL-6 deficiency exacerbated high-fat dietinduced hepatic insulin resistance and inflammation which appeared to be related to defects in mitochondrial metabolism [22].”
BackgroundSteensberg, A., van Hall, G., Osada, T., Sacchetti, M., Saltin, B., & Pedersen, B. K. (2000) · The Journal of Physiology · doi:10.1111/j.1469-7793.2000.00237.x · Cited by 1,095 · cited 2×
“In complementary studies from the Pedersen [16] and Febbraio [17] laboratories published a decade ago, it was discovered that the vast majority of exercise-induced IL-6 arose from skeletal muscle, rather than adipose tissue, as is the case with obesity.”
BackgroundCarey, A. L., Steinberg, G. R., Macaulay, S. L., Thomas, W. G., Holmes, A. G., Ramm, G., Prelovsek, O., Hohnen-Behrens, C., Watt, M. J., James, D. E., et al. (2006) · Diabetes · doi:10.2337/db05-1404 · Cited by 898 · cited 6×
“These positive metabolic effects of IL-6 appear to be mediated by activation of AMPK, a drug target for many metabolic diseases, and the protein kinase activated by the biguanide class of antidiabetic drugs such as metformin.”
BackgroundInfluentialSelf-citationAblation of CD11c-Positive Cells Normalizes Insulin Sensitivity in Obese Insulin Resistant Animals
Patsouris, D., Li, P.-P., Thapar, D., Chapman, J., Olefsky, J. M., & Neels, J. G. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.08.015 · Cited by 804 · cited 1×
“[38] used a conditional cell deletion system, based on transgenic expression of the diphtheria toxin receptor under the control of the CD11c promoter, to study the effects of depletion of CD11c+ cells in obese mouse models.”
MethodMaini, R. N., Taylor, P. C., Szechinski, J., Pavelka, K., Bröll, J., Balint, G., Emery, P., Raemen, F., Petersen, J., Smolen, J., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22033 · Cited by 790
Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease
Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4602 · Cited by 754
Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue
Kosteli, A., Sugaru, E., Haemmerle, G., Martin, J. F., Lei, J., Zechner, R., & Ferrante, A. W. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42845 · Cited by 726 · cited 2×
“Recent data suggests that these M2 macrophages are dynamically recruited into adipose tissue during times of increased lipolysis [37].”
BackgroundSubcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor- , in Vivo
Mohamed-Ali, V. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.12.4196 · Cited by 717
Cited by
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Interleukin-6: designing specific therapeutics for a complex cytokine
Garbers, C., Heink, S., Korn, T., & Rose-John, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.45 · Cited by 643
The Ever-Expanding Myokinome: Discovery Challenges and Therapeutic Implications
Whitham, M., & Febbraio, M. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.153 · Cited by 279
From cytokine to myokine: The emerging role of interleukin-6 in metabolic regulation
Pal, M., Febbraio, M. A., & Whitham, M. (2014) · Immunology & Cell Biology · doi:10.1038/icb.2014.16 · Cited by 258
Self-citationKraakman, M. J., Kammoun, H. L., Allen, T. L., Deswaerte, V., Henstridge, D. C., Estevez, E., Matthews, V. B., Neill, B., White, D. A., Murphy, A. J., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.02.006 · Cited by 257
Self-citation
Metadata
- Authors
- Kraakman, M. J., Allen, T. L., Whitham, M., Iliades, P., Kammoun, H. L., Estevez, E., Lancaster, G. I., & Febbraio, M. A.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2013-09
- Volume
- 15
- Issue
- s3
- Pages
- 170-175
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2049628763
- Cited by
- 33
- References
- 20
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting gp130 to prevent inflammation and promote insulin action. https://app.cochat.ai/papers/10.1111/dom.12170
- The paper
- Kraakman, M. J., Allen, T. L., Whitham, M., Iliades, P., Kammoun, H. L., Estevez, E., Lancaster, G. I., & Febbraio, M. A. (2013). Targeting gp130 to prevent inflammation and promote insulin action. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12170
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.